Ketek is a drug that has been approved in 2004 for the treatment of acute bacterial infections from chronic bronchitis, acute bacterial sinusitis and community-acquired pneumonia. There has been a link to Ketek ib reports of severe liver problems and deaths. As ar result the drug will be subjected to new scrutiny by the FDA.
The FDA will discuss the overall risks and benefits of the antibiotic Ketek during a Dec. 14-15 meeting, according to their site.
The joint panel's two-day review of Ketek could lead to a recommendation that the agency add further warnings to the label of the drug.
Ketek, also called telithromycin, carries a bold-type warning about the rare reports of liver failure and severe injury, some of them fatal, in patients treated with the drug.
For more, go here.